GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
IDERA PHARMACEUTICAL (IDRA) [hlAlert]

Rating:
Buy IDRA
down 51.51 %

IDERA PHARMACEUTICAL (IDRA) rated Buy by Noble Financial

Posted on: Friday,  Nov 21, 2008  10:25 AM ET by Noble Financial

Noble Financial rated Buy IDERA PHARMACEUTICAL (NASDAQ: IDRA) on 11/21/2008, when the stock price was $5.96. Since
then, IDERA PHARMACEUTICAL has lost 51.51% as of 08/27/2015's recent price of $2.89.
If you would have followed this Noble Financial's recommendation on IDRA, you would have lost 51.51% of your investment in 2470 days.

Idera Pharmaceuticals, Inc. (Idera) is a biotechnology company. The Company is engaged in the discovery and development of synthetic deoxyribonucleic acid (DNA)-and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. TLRs are specific receptors present in immune system cells that recognize the DNA or RNA of pathogens, such as bacteria or viruses and initiate an immune response. IMO-2125, a TLR9 agonist, is the Company lead drug candidate for infectious diseases. As part of the Company?s infectious disease program, it is also evaluating RNA-based compounds that act as agonists of TLR7 and TLR8.

A clear and concise focus. Identifying the emerging small or micro cap company. Recognizing the entrepreneurial character and organizational commitment of its executives and employees. Observing unstoppable drive to exploit opportunities while tackling obstacles. Understanding the company's essential products, services and technologies. Following only those who deserve our attention.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/21/2008 10:25 AM Buy
None
5.96
as of 12/24/2008
1 Week down  -4.16 %
1 Month down  -10.34 %
3 Months down  -22.13 %
1 YTD down  -22.13 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy